Suggested remit: To appraise the clinical and cost effectiveness of maralixibat within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 3818
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 September 2023 | Note - Note added to the project documents |
| 07 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 22 August 2023 | Note added to the project documents |
| 22 August 2023 | Topic selection |
| 20 March 2023 - 19 April 2023 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 3818 |
| 20 March 2023 | In progress |
| 21 December 2022 | Discontinued |
| 29 October 2021 | Suspended |
| 01 March 2021 (14:00) | Scoping workshop |
| 08 January 2021 - 05 February 2021 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 08 January 2021 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual